Molecular Mobility of N ‐Acetylgalactosamine‐Modified Cyclodextrins on a Polyrotaxane for Highly Efficient Liver Targeting of Antibody Chimeras and Genome‐Editing Ribonucleoproteins
Advanced Science · 2026
DOI: 10.1002/advs.75996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Toru Taharabaru und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Rotaxanes, Acetylgalactosamine, Cyclodextrins, Poloxamer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Platform for All Regions of Kyushu & Okinawa for Startup-ecosystem (PARKS), Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (JSPS), Grant-in-Aid for Early-Career Scientists from JSPS.
Themen: Mobilisation
Abstract (Originalsprache)
Triantennary N ‐acetylgalactosamine ( tri GalNAc), which interacts strongly with the trimeric structure of asialoglycoprotein receptors (ASGPRs), is a validated platform for liver targeting. However, the intricate design and synthesis of its linkers impose high production costs and significant technical challenges. In this study, we report an alternative strategy for targeting ASGPR using monovalent GalNAc ( mono GalNAc) conjugated to the cyclic molecules of polyrotaxane, which can rotate and translocate along the axial polymer chain. The intracellular uptake efficacy of mono GalNAc‐modified polyrotaxane is comparable to that of tri GalNAc‐modified polyrotaxane and significantly higher than that of tri GalNAc‐ or mono GalNAc‐modified immobile control polymers. These results suggest that the inherent mobility of polyrotaxanes allows mono GalNAc moieties to cluster in a trivalent‐like manner, thereby enhancing multivalent interactions with multiple ASGPR oligomers. The successful application of mono GalNAc‐modified polyrotaxane to lysosome‐targeting antibody chimeras and genome‐editing nanoparticles demonstrates that this facile technology is a highly promising alternative to conventional tri GalNAc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Toru Taharabaru, Jun Li
Förderung
- Platform for All Regions of Kyushu & Okinawa for Startup-ecosystem (PARKS)
- Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (JSPS)
- Grant-in-Aid for Early-Career Scientists from JSPS
- Grant-in-Aid for JSPS Research Fellows
- JSPS Overseas Challenge Program for Young Researchers
- The New Pharmaceutical Technology and Engineering Foundation
- Academic Research Fund Tier 2 Grant from Singapore's Ministry of Education
Zitieren
APA
Taharabaru, T., Motoyama, K., Wen, Y., Zhang, Z., Tian, X., Li, J., & Higashi, T. (2026). Molecular Mobility of N ‐Acetylgalactosamine‐Modified Cyclodextrins on a Polyrotaxane for Highly Efficient Liver Targeting of Antibody Chimeras and Genome‐Editing Ribonucleoproteins. Advanced Science. https://doi.org/10.1002/advs.75996
Vancouver
Taharabaru T, Motoyama K, Wen Y, Zhang Z, Tian X, Li J, et al. Molecular Mobility of N ‐Acetylgalactosamine‐Modified Cyclodextrins on a Polyrotaxane for Highly Efficient Liver Targeting of Antibody Chimeras and Genome‐Editing Ribonucleoproteins. Advanced Science. 2026. doi:10.1002/advs.75996
BibTeX
@article{Taharabaru2026,
author = {Taharabaru, Toru and Motoyama, Keiichi and Wen, Yuting and Zhang, Zhongxing and Tian, Xuehao and Li, Jun and Higashi, Taishi},
title = {Molecular Mobility of N ‐Acetylgalactosamine‐Modified Cyclodextrins on a Polyrotaxane for Highly Efficient Liver Targeting of Antibody Chimeras and Genome‐Editing Ribonucleoproteins},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75996}
}
EUVIMED